A Phase 2 interventional study of Risankizumab and Placebo for risankizumab in Hidradenitis Suppurativa, sponsored by AbbVie. Completed at 59 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-11.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 11th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in Argentina, Canada, Colombia and 15 more countries
Ages 12+
AbbVie · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 243 across the 11 interventional studies, 106 across the 6 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
3 of the studies in Hidradenitis Suppurativa by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06524635AbbVieA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | 2027-02 |
| NCT07136467AbbVieA Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Hidradenitis Suppurativa by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
Drug: Risankizumab
In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
Drug: Risankizumab
In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12.
Drug: Placebo for risankizumab
In Period A, participants receive blinded risankizumab 180 mg via a subcutaneous (SC) injection at Weeks 0 (Baseline), 1, 2, 4, and 12. In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg every 8 weeks (q8w) at Weeks 20, 28, 36, 44, 52, and 60.
Drug: Risankizumab · Drug: Placebo for risankizumab
In Period A, participants receive blinded risankizumab 360 mg via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12. In Period B, participants receive blinded placebo at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60.
Drug: Risankizumab · Drug: Placebo for risankizumab
In Period A, participants receive blinded placebo via a SC injection at Weeks 0 (Baseline), 1, 2, 4, and 12. In Period B, participants receive blinded risankizumab 360 mg at Weeks 16, 17, and 18. Starting at Week 20, participants receive open-label risankizumab 360 mg q8w at Weeks 20, 28, 36, 44, 52, and 60.
Drug: Risankizumab · Drug: Placebo for risankizumab
Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Also known as: ABBV-066, SKYRIZI
Placebo for risankizumab is administered as a SC injection in PFS
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
HiSCR is defined as at least a 50% reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess or draining fistula counts.
Time frame: Baseline (Week 0), Week 16
Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in Patient's Global Assessment (PGA) of Skin Pain Numerical Rating Scale (NRS30) at Week 8 Among Participants With Baseline Numerical Rating Scale (NRS) ≥ 3
NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline at Week 8 in the PGA of Skin Pain (NRS30) - at worst, among participants with Baseline NRS ≥ 3, is presented.
Time frame: Baseline (Week 0) to Week 8
Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in PGA of Skin Pain Numerical Rating Scale (NRS30) at Week 16 Among Participants With Baseline Numerical Rating Scale (NRS) ≥ 3
NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline at Week 16 in the PGA of Skin Pain (NRS30) - at worst, among participants with Baseline NRS ≥ 3, is presented.
Time frame: Baseline (Week 0) to Week 16
Percentage of Participants Who Experienced ≥ 25% Increase in Abscess and Inflammatory Nodule (AN) Counts in Period A With a Minimum Increase of 2 Relative to Baseline
Time frame: Baseline (Week 0) to Week 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
The DLQI is a 10-item validated questionnaire used to assess the impact of HS disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. DLQI scores range from 0 to 30, with a higher score indicating a more impaired QoL.
Time frame: Baseline (Week 0) to Week 16
Change From Baseline in HS-Related Swelling Based on the Hidradenitis Suppurativa Symptom Assessment (HSSA) Swollen Skin Score at Week 16
HSSA is a 9-item participant-reported outcome (PRO) questionnaire developed to assess the symptoms of HS. HS-related swelling is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
Time frame: Baseline (Week 0) to Week 16
Change From Baseline in HS-Related Odor Based on the HSSA Bad Smell Score at Week 16
HSSA is a 9-item PRO questionnaire developed to assess the symptoms of HS. HS-related odor is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
Time frame: Baseline (Week 0) to Week 16
Change From Baseline in HS-Related Worst Drainage Based on the HSSA Worst Drainage Score at Week 16
HSSA is a 9-item PRO questionnaire developed to assess the symptoms of HS. HS-related worst drainage is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
Time frame: Baseline (Week 0) to Week 16
| Milestone | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg |
|---|---|---|---|
| Started | 82 | 80 | 81 |
| Never received study drug | 0 | 0 | 1 |
| Completed | 74 | 70 | 75 |
| Not completed | 8 | 10 | 6 |
| Withdrew: Adverse event | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 2 |
| Withdrew: Covid-19 infection | 0 | 1 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 2 | 1 |
| Withdrew: Other, not specified | 1 | 0 | 0 |
| Milestone | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg |
|---|---|---|---|
| Started | 74 | 70 | 75 |
| Entered period b and received study drug | 74 | 70 | 74 |
| Completed | 4 | 7 | 4 |
| Not completed | 70 | 63 | 71 |
| Withdrew: Adverse event | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 4 |
| Withdrew: Other, not specified | 62 | 57 | 65 |
HiSCR is defined as at least a 50% reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess or draining fistula counts.
| percentage of participants | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 41.5 (29.3 to 53.7) | 46.8 (34.2 to 59.4) | 43.4 (31.0 to 55.8) |
NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline at Week 8 in the PGA of Skin Pain (NRS30) - at worst, among participants with Baseline NRS ≥ 3, is presented.
| percentage of participants | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in Patient's Global Assessment (PGA) of Skin Pain Numerical Rating Scale (NRS30) at Week 8 Among Participants With Baseline Numerical Rating Scale (NRS) ≥ 3 | 33.0 (19.4 to 46.5) | 29.2 (15.9 to 42.6) | 40.0 (25.8 to 54.2) |
NRS30 is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline at Week 16 in the PGA of Skin Pain (NRS30) - at worst, among participants with Baseline NRS ≥ 3, is presented.
| percentage of participants | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in PGA of Skin Pain Numerical Rating Scale (NRS30) at Week 16 Among Participants With Baseline Numerical Rating Scale (NRS) ≥ 3 | 27.9 (15.0 to 40.7) | 31.1 (17.5 to 44.7) | 38.6 (24.4 to 52.7) |
| percentage of participants | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced ≥ 25% Increase in Abscess and Inflammatory Nodule (AN) Counts in Period A With a Minimum Increase of 2 Relative to Baseline | 29.3 (18.0 to 40.5) | 22.5 (12.0 to 33.0) | 18.5 (8.8 to 28.2) |
The DLQI is a 10-item validated questionnaire used to assess the impact of HS disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. DLQI scores range from 0 to 30, with a higher score indicating a more impaired QoL.
| score on a scale | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16 | -2.1 (-3.9 to -0.4) | -3.5 (-5.2 to -1.8) | -3.7 (-5.5 to -2.0) |
HSSA is a 9-item participant-reported outcome (PRO) questionnaire developed to assess the symptoms of HS. HS-related swelling is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
| score on a scale | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Change From Baseline in HS-Related Swelling Based on the Hidradenitis Suppurativa Symptom Assessment (HSSA) Swollen Skin Score at Week 16 | -0.870 (-1.416 to -0.324) | -0.751 (-1.338 to -0.165) | -0.885 (-1.436 to -0.334) |
HSSA is a 9-item PRO questionnaire developed to assess the symptoms of HS. HS-related odor is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
| score on a scale | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Change From Baseline in HS-Related Odor Based on the HSSA Bad Smell Score at Week 16 | -0.677 (-1.160 to -0.195) | -0.635 (-1.149 to -0.120) | -0.442 (-0.928 to 0.044) |
HSSA is a 9-item PRO questionnaire developed to assess the symptoms of HS. HS-related worst drainage is scored on an 11-point NRS, where 0 represents no symptoms and 10 represents extreme symptom experience.
| score on a scale | Placebo | Risankizumab 180 mg | Risankizumab 360 mg |
|---|---|---|---|
| Change From Baseline in HS-Related Worst Drainage Based on the HSSA Worst Drainage Score at Week 16 | -0.630 (-1.154 to -0.107) | -0.882 (-1.440 to -0.324) | -0.705 (-1.233 to -0.176) |
Collected over From the first dose of study medication until 20 weeks after the last dose. Part A overall mean duration on study drug was 108.5 days. Part B overall mean duration on study drug was 179.9 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/82 (0%) | 2/82 (2.4%) | 19/82 (23.2%) |
| Risankizumab 180 mg | 0/80 (0%) | 3/80 (3.8%) | 21/80 (26.3%) |
| Risankizumab 360 mg | 0/80 (0%) | 2/80 (2.5%) | 26/80 (32.5%) |
| Placebo / Risankizumab 360 mg | 0/74 (0%) | 3/74 (4.1%) | 26/74 (35.1%) |
| Risankizumab 180 mg / Risankizumab 360 mg | 0/70 (0%) | 4/70 (5.7%) | 12/70 (17.1%) |
| Risankizumab 360 mg / Risankizumab 360 mg | 0/74 (0%) | 0/74 (0%) | 19/74 (25.7%) |
| Event | Placebo | Risankizumab 180 mg | Risankizumab 360 mg | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg |
|---|---|---|---|---|---|---|
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/82 | 0/80 | 1/80 | 0/74 | 1/70 | 0/74 |
| TONSILLITISInfections and infestations | 0/82 | 0/80 | 0/80 | 0/74 | 1/70 | 0/74 |
| URINARY TRACT INFECTIONInfections and infestations | 0/82 | 0/80 | 0/80 | 0/74 | 1/70 | 0/74 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 0/82 | 0/80 | 0/80 | 0/74 | 1/70 | 0/74 |
| DEEP VEIN THROMBOSISVascular disorders | 0/82 | 0/80 | 0/80 | 0/74 | 1/70 | 0/74 |
| APPENDICITISInfections and infestations | 0/82 | 0/80 | 0/80 | 1/74 | 0/70 | 0/74 |
| CELLULITISInfections and infestations | 0/82 | 0/80 | 0/80 | 1/74 | 0/70 | 0/74 |
| BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 0/80 | 0/80 | 1/74 | 0/70 | 0/74 |
| ENDOMETRIOSISReproductive system and breast disorders | 0/82 | 0/80 | 0/80 | 1/74 | 0/70 | 0/74 |
| OVARIAN CYSTReproductive system and breast disorders | 0/82 | 0/80 | 0/80 | 1/74 | 0/70 | 0/74 |
| Event | Placebo | Risankizumab 180 mg | Risankizumab 360 mg | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg |
|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 9/82 | 6/80 | 11/80 | 7/74 | 1/70 | 4/74 |
| HIDRADENITISSkin and subcutaneous tissue disorders | 7/82 | 3/80 | 2/80 | 6/74 | 8/70 | 10/74 |
| NASOPHARYNGITISInfections and infestations | 3/82 | 6/80 | 7/80 | 1/74 | 4/70 | 1/74 |
| DIARRHOEAGastrointestinal disorders | 4/82 | 2/80 | 2/80 | 5/74 | 1/70 | 2/74 |
| URINARY TRACT INFECTIONInfections and infestations | 1/82 | 4/80 | 3/80 | 4/74 | 0/70 | 0/74 |
| ECZEMASkin and subcutaneous tissue disorders | 0/82 | 0/80 | 2/80 | 1/74 | 0/70 | 4/74 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/82 | 1/80 | 4/80 | 2/74 | 0/70 | 0/74 |
| BACK PAINMusculoskeletal and connective tissue disorders | 2/82 | 3/80 | 4/80 | 2/74 | 0/70 | 1/74 |
| Age, Continuous(years) | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg | Total |
|---|---|---|---|---|
| Mean | 37.2 ± 11.97 | 38.9 ± 11.45 | 38.2 ± 11.99 | 38.1 ± 11.77 |
| Sex: Female, Male(Participants) | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg | Total |
|---|---|---|---|---|
| Female | 48 | 53 | 51 | 152 |
| Male | 34 | 27 | 30 | 91 |
| Race/Ethnicity, Customized(Participants) | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 10 | 7 | 26 |
| Not Hispanic or Latino | 73 | 70 | 74 | 217 |
| Race/Ethnicity, Customized(Participants) | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg | Total |
|---|---|---|---|---|
| White | 68 | 63 | 62 | 193 |
| Black or African American | 4 | 12 | 9 | 25 |
| Asian | 8 | 4 | 9 | 21 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Multiple Races | 2 | 0 | 1 | 3 |
| Abscess and Inflammatory Nodule (AN) Count(abscess and inflammatory nodules) | Placebo / Risankizumab 360 mg | Risankizumab 180 mg / Risankizumab 360 mg | Risankizumab 360 mg / Risankizumab 360 mg | Total |
|---|---|---|---|---|
| Mean | 15.7 ± 28.42 | 13.7 ± 11.42 | 12.5 ± 8.24 | 14.0 ± 18.36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jun 2019 to primary completion in Feb 2021, 19 months.
Results were first posted in Aug 2022, 1 year 6 months after primary completion. A results delay was requested in Jan 2022.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 19 months is above that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab